The US Deprescribing Research Network
Pilot and Grant Planning Awards
Information for Potential Applicants

AMANDA MIXON, MD
SANDRA SIMMONS, PHD
JOANNA GUPTA, MED
Disclosures

• No relevant disclosures

• Thank you!
  • NIA R24 AG064025-1
  • Scientific Advisory Board
  • Joanna Gupta, Malena Spar, Jonathan Norton, Anael Rizzo
What is the network?

Leadership & Administration Core
Co-PIs: C. Boyd, MD; M. Steinman, MD

Executive Committee
Core Co-Directors

Scientific advisory board

Investigator Development Core
J. Tija, MD
K. Boockvar, MD

Data and Resources Core
E. Bayliss, MD
S. Dublin, MD PhD

Stakeholder Engagement Core
C. Sarkisian, MD
N. Brandt, PharmD

Pilot and Exploratory Studies Core
S. Simmons, PhD
A. Mixon, MD

Working Groups (4)
Five pillars

• Investigator development
• Stakeholder engagement
• Data and resources
• Working Groups
• Funding for pilot studies and grant-planning activities
Pilot Awards: Purpose

• Support early-stage research in deprescribing that has high potential to develop into future larger projects

• Funding will be provided primarily, but not exclusively, to junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.
Pilot and Grant Planning Awards: Types

• Pilot Award

• Grant Planning Award

For full descriptions, refer to:
https://deprescribingresearch.org/network-activities/grant-opportunities/
Scope of Pilot Grants
### Scope of Pilot Projects

<table>
<thead>
<tr>
<th>Projects should:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Have a direct and clear relationship to deprescribing</td>
</tr>
<tr>
<td>• Be relevant to the care of older adults</td>
</tr>
<tr>
<td>• Demonstrate a clear pathway to future grants, research opportunities, and/or career development focused on deprescribing</td>
</tr>
</tbody>
</table>
Scope: Definition of Deprescribing

‘Deprescribing is the process of withdrawal, dose reduction or substitution of an inappropriate (high risk, unnecessary, low benefit) medication, supervised by a health care professional with the goal of managing polypharmacy (also relevant for those without ‘polypharmacy’) and improving outcomes.’

-University of South Australia

See also: https://deprescribingresearch.org/about-us/what-is-deprescribing/
Pilot and Grant Planning Awards--Year 1

• Decisions about anticoagulation in patients with atrial fibrillation and dementia (Greg Ouellet, MD, MHS, Yale)

• Older adults’ attitudes and preferences about how deprescribing recommendations are discussed (Ariel Green, MD, MPH, PhD and Nancy Schoenborn, MD, Johns Hopkins)

• Intensification and deintensification of glucose-lowering therapies among older adults with diabetes mellitus and multiple chronic conditions (Jen Kuntz, PhD, Kaiser Permanente Northwest)
Eligibility Criteria
Applicant Eligibility

• Hold a Doctoral degree (MD, PhD or equivalent)

• Employed as faculty, research scientist or equivalent position by start date of award

• Work in a college, university, medical or nursing school, or other fiscally responsible institution registered with System Award Management (SAM)

• Only one application per individual but two or more are allowed from the same institution
Applicant Eligibility Continued

• Eligible researchers at non-US institutions will be considered, but articulate how the proposed research will apply outside the home country, including the U.S.

• Applicants from under-represented racial and ethnic groups, socioeconomically-disadvantaged backgrounds, as well as individuals with disabilities encouraged to apply
Available Funds
Available Funds

• Up to $60,000 in total costs (direct + indirect)
  • Indirect costs charged by recipient institution’s federally negotiated rate
  • Foreign organizations may charge no more than 8% of modified total direct costs

• Distributed in August or September 2020 for use over a one-year period

• Three to five pilot awards per year
First Funding Mechanism: Pilot Award

<table>
<thead>
<tr>
<th>Funding will be provided primarily but not exclusively to junior investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed study provides preliminary data, proof of concept, or developmental work that provides a clear pathway to future larger-scale studies</td>
</tr>
<tr>
<td>Different study designs are encouraged, including pilot research that may lead to future clinical trials, observational studies, and/or in-depth qualitative evaluation.</td>
</tr>
</tbody>
</table>
Second Funding Mechanism: Grant Planning Award

Funding will be provided primarily but not exclusively to more established investigators

Researcher must be focused on grant planning activities that will lead to a larger research proposal
Submission Materials
Letters of Intent

Optional but encouraged, especially when:

- Requesting more than the budget cap or >1 year of funding (in special circumstances); feedback sought
- Details to include:
  - Research team
  - Stakeholder engagement
  - Aims, approach, and/or grant-planning activities
- Guidelines: [https://deprescribingresearch.org/network-activities/grant-opportunities/](https://deprescribingresearch.org/network-activities/grant-opportunities/)
- Submit to: admin@deprescribingresearch.org

Formatting: 1 page, ½” margins, 11-point Arial font
Due Monday, February 10, 2020, 11:59 PM (PST)
# Pilot and Grant Planning Awards: Requirements

<table>
<thead>
<tr>
<th>Sections</th>
<th>Pilot</th>
<th>Grant Planning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Aims</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Significance</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Innovation</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Approach</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Future Directions</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Stakeholder Engagement</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Maximum of 5 pages (including cover), ½” margins, 11-point Arial font
Due Monday, March 9, 2020, 11:59 (PST)
Grant Planning Award

Additional Required Sections:

- Grant Planning Activities—aims and approaches for larger-scale study
- Funding Mechanisms—how work will lead to grants, publications, etc.
Both RFA’s

Stakeholder Engagement:

- Description of stakeholders
- Details on their engagement
- Information on how they will inform work
- Timeline of their study-related activities
- Settings and methods of engagement
## Required Supplemental Materials

- Half-page project description in lay terminology for stakeholders
- NIH-style biosketch
- Junior investigators:
  - One-page mentoring plan
  - Mentor’s letter of support
- Budget forms
Required Supplemental Materials Continued

Budget Forms:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Budget summary</td>
<td></td>
</tr>
<tr>
<td>Budget justification</td>
<td></td>
</tr>
<tr>
<td>Scope of work</td>
<td></td>
</tr>
<tr>
<td>F&amp;A rate agreement</td>
<td></td>
</tr>
</tbody>
</table>

Does not count toward 5 page limit
Due Monday, March 9, 2020, 11:59 (PST)
Submit Online

https://deprescribingresearch.org/network-activities/grant-opportunities/

Grant Opportunities

The network funds pilot and exploratory studies, grant planning activities, and small collaboration grants. The goals of these grant programs are to support early-stage research in deprescribing that has high potential to develop into future large projects, to catalyze research in areas that are of particular importance to the field, to support junior investigator development, and to promote collaborations that will lead to future research projects.

- Learn about and apply for a pilot or exploratory studies award
- Learn about and apply for a grant planning award
- Learn about and apply for a collaboration award
- Learn about network grantees and their projects
Submit Online
<table>
<thead>
<tr>
<th>Event</th>
<th>Date/Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letters of Intent (optional)</td>
<td>Monday, February 10, 2020, 11:59 PM (PST)</td>
</tr>
<tr>
<td>Full application</td>
<td>Monday, March 9, 2020, 11:59 (PST)</td>
</tr>
<tr>
<td>Awards announced</td>
<td>June 1, 2020</td>
</tr>
<tr>
<td>Beginning of funding for selected awards</td>
<td>August or September 2020</td>
</tr>
</tbody>
</table>
Expectations and Resources for Awardees
Expectations and Resources

Year End Progress Report

Present Work at the Annual Meeting

Yearly Online Surveys After Award Period
Additional Expectations and Resources for Junior Investigators

- Quarterly Calls with Pilot Core
- Quarterly Calls with Stakeholder Engagement Core
- Optional USDeN Webinars and Work-in Progress Seminars
First Annual USDeN Meeting
May 6th, 2020, Long Beach, CA

KEYNOTE: CARA TANNENBAUM, MD, MSC

CO-FOUNDER AND CO-DIRECTOR OF THE CANADIAN DEPRESCRIBING NETWORK

- Share research
- Access resources of USDeN
- Stakeholder engagement
- Networking
- Junior Investigator Supports

AND MORE....!
Upcoming Webinar

- Tues, February 4, 2020 at 2pm Eastern
- Shed-MEDS – A Hospital-based Deprescribing Trial Among Older Patients Transferred to Post-Acute Care
- Sandra Simmons, PhD and Ed Vasilevskis, MD, MPH
Junior Investigator Intensive Program

• The US Deprescribing Research Network seeks applicants for its 2020-2021 Junior Investigator Intensive Program in deprescribing research

• Program components:
  • Special evening meeting following the Annual Meeting on May 6, 2020 in Long Beach, CA
  • Monthly web-based meetings
  • Access to USDeN resources

• Applications due: March 1, 2020

• Visit deprescribingresearch.org for more information
DeprescribingResearch.org

Advancing research to optimize medication use among older adults.
Questions or Comments